GREY:ATBPF - Post by User
Comment by
Actuarialon Feb 13, 2021 9:31am
165 Views
Post# 32561275
RE:RE:Nasdaq
RE:RE:NasdaqATE and IMV are very different. IMV relies on other company collaboration - its drug would not treat cancer but it would extend others stimulation to immune system - for example, combination with Keytruda from Merck. Also, IMV institutional investors own 35.7% of IMV already. Assume some percentage of ATE will be bought by institutional investors after Nasdaq. That will push ATE share price much much higher. In addition, before Nasdaq, its share price was only $1.5. The price right after Nasdaq was $6.5. Even now the price is around $4. How come you say Nasdaq not help in share price? The share price start to run up usually once a company announce uplisting. If you count only after actually uplisting, that would severely underestimate the impact. That's my 2 cents based on my observation.
JimmyJ wrote: An uplist on Nasdaq is not a guaranteed raise in share price. Take IMV for example. IMV listed on nasdaq on May 31st, 2018. They have a novel immunotherapy delivery platform to treat ovarian cancer called dlbc/dpx survicac. They competed Phase 2 last year and the efficacy showed it can be the best type of treatment on the market for that cancer. Where i believe IMV faulted, was managements inability to keep the markets interested with regular news updates. The business is ran by scientists whereas ATE's management has a good balance of science and business savvy people. If ATE keeps a steady stream of news every few weeks, we are hitting $9 in no time. If it gets quiet for a couple months, I can see this stick around here for a while still. Just my 0.02 cents and past experience in biotech. GLTA